Two of the other drugs singled out by our screen, mefloquine and isradipine, have more direct evidence supporting their ability to mitigate excitotoxic brain damage: mefloquine, an antimalarial drug, has been shown to prevent excitotoxicity-induced neuronal death in animal models of both stroke [123] and traumatic brain injury [124], owing to its potent blockade of Cx36-containing gap junctions. The gene discussed is GJD2; the disease is Stroke.